SAGA enters collaboration with Institut Curie in the MONDRIAN trial

LUND, Sweden — /February 2, 2021/ — SAGA Diagnostics AB, a cancer liquid biopsy and genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients, announced today its collaboration with the French comprehensive cancer center Institut Curie in the MONDRIAN breast cancer clinical trial.

 

The Institut Curie is the leading European center for breast cancer treatment in Paris, France, and one of the largest in Europe.

 

The MONDRIAN trial is a prospective single arm phase II clinical study to assess the clinical utility of monitoring early chemotherapy response using circulating tumor DNA (ctDNA) for patients with HER2-negative metastatic breast cancer (ClinicalTrials.gov NCT04720729).

 

The MONDRIAN trial will be pivotal to show the clinical utility of early monitoring by circulating tumor DNA to predict the response to therapies in advanced breast cancer and improve patient outcomes. If treatment response or resistance is found significantly earlier, the hope is that a more personalized treatment can be more effective, which could make a difference for thousands of patients every year.
Professor François-Clément Bidard, principal investigator of the MONDRIAN trial

 

SAGA Diagnostics will provide SAGAsafe® digital PCR assays that will be used to monitor the circulating tumor DNA of more than 200 patients at baseline and during treatment. SAGAsafe® technology is a patented enhancement of digital PCR offering a sensitivity that is up to 100x increased in comparison with competitor methods. SAGAsafe® can be used to detect and quantify mutations in tissue samples as well as liquid biopsies such as blood plasma.

 

We at SAGA are honored to be working with the Institut Curie and are looking forward to this exciting collaboration. We are convinced that the unrivaled sensitivity of the SAGAsafe® assays developed will provide the best possible outcome for this clinical study showcasing the potential that liquid biopsies provide in cancer monitoring and the benefits of ctDNA analysis for breast cancer patients.
– Dr. Johanna Asklin, Director of Operations at SAGA Diagnostics

 

The MONDRIAN trial will start in March 2021 and will run for two years. It is sponsored and organized by the Institut Curie, and SAGA will be part of the executive committee of the study.

 


 

Contact: CEO Lao Saal, MD PhD.   media@sagadiagnostics.com   Phone: +46 (0) 733 01 7242

 

About SAGA Diagnostics AB
SAGA Diagnostics is a personalized cancer genomics and disease monitoring company that offers molecular genetic testing of tissue biopsies and non-invasive “liquid biopsies” such as blood samples. SAGA helps pharmaceutical companies, scientists, and healthcare providers to detect actionable mutations, stratify patient groups, and monitor treatment response more accurately and to an industry-leading lower limit of detection of 0.001%. Analysis of circulating tumor DNA using its proprietary technologies gives SAGA unique ultrasensitivity, and provides the basis for optimal decision-making.

Follow SAGA on Twitter @SAGAdiagnostics and LinkedIn.